What is the significance of the Chinese market to leading biopharmaceutical companies? Pablo Soriot, global CEO of AstraZeneca, one of the leading international biopharmaceutical companies, told reporters in an interview on the 26th: "China plays a vital role in the global healthcare industry. It is not only a leader in innovation, but also plays a key role in the global research and development and production of important drugs. For AstraZeneca, the Chinese market is crucial."Biopharmaceutical Industry International Development Conference" held on the same day , AstraZeneca officially announced that Shanghai would become its fifth global strategic center. The "Shanghai Biopharmaceutical Innovation Enterprise 2024 Overseas Cooperation Plan" was officially released on the same day, enabling local innovative drugs to reach a new level and helping Chinese innovation lead global pharmaceutical innovation.

It is reported that in the future, Shanghai, China will become another global strategic center integrating R&D, commercial and production operations, in addition to AstraZeneca's four major R&D-focused strategic centers in Cambridge, UK, Boston, USA, Gaithersburg, USA and Gothenburg, Sweden, and will become an important strategic fulcrum for AstraZeneca's global strategy, R&D and long-term development.

It is reported that biomedicine is one of the three leading industries that Shanghai focuses on developing. Shanghai is one of the innovation centers of China's modern pharmaceutical industry, with complete development factors, a sound industrial ecology, and increasing international influence. In recent years, Shanghai has made important progress in the development of the biomedicine industry, with the scale of the industry increasing by 4.9% year-on-year in 2023. The "2024 Shanghai Biomedicine Industry International Development Conference" held on the same day was themed "Facing the World, Going Overseas" and hoped to promote exchanges and dialogues in the field of biomedicine, explore multilateral industrial cooperation, and promote the internationalization and high-quality development of Shanghai's medical industry.

During the interview, the reporter learned that the "Shanghai Biomedical Innovation Enterprise 2024 Cooperation Overseas Plan" aims to deepen cooperation with China's local innovation forces and continuously build an important platform for going global. The plan will cover emerging markets in the countries that jointly build the "Belt and Road" and countries in Europe, the United States, Japan, etc., and will help 30 outstanding Shanghai companies go overseas in the form of two-way visits and docking, and continue to promote cross-border cooperation and exchanges in pharmaceutical innovation. AstraZeneca said that it will actively help Shanghai become the origin of pharmaceutical innovation results and the "home port" for China's innovation overseas.

It is reported that this plan will promote Shanghai's medical innovation enterprises to further expand into the international market, strengthen the connection between Shanghai and the international innovation ecosystem through innovation "going global", and enhance Shanghai's international reputation as a science and technology innovation center. The launch event brought together AstraZeneca's business leaders in Latin America, the Middle East and Africa, and Asia, as well as guest representatives from six local innovative pharmaceutical companies.

As an important city participating in international biopharmaceutical industry competition and innovation cooperation, Shanghai is accelerating its progress towards a science and technology innovation center with global influence, providing important support for local medical innovation companies to move towards international development. The government strongly supports original innovation and increases investment in basic research year by year. In recent years, Shanghai has adhered to the innovation source and actively promoted innovative biopharmaceutical companies to accelerate the process of research and development, industrialization, commercialization and globalization.

This conference brought together well-known people from many fields such as industry, academia, research, medicine, and finance, actively promoted the deep collision of ideas and multi-dimensional exchanges in the industrial chain, and injected innovative momentum into Shanghai's biopharmaceutical industry. During the conference, two roundtable meetings attended by government leaders, academicians of the two academies, university professors, senior executives of domestic and foreign biopharmaceutical companies, heads of multinational industry institutions, and "heads" of top investment institutions discussed the road to innovation in the development of biopharmaceuticals.

The Shanghai Municipal Science and Technology Commission said that in the next step, Shanghai will adhere to the systematic promotion of the entire industry chain of "R&D + clinical + manufacturing + application", with the improvement of innovation source capabilities as the main direction, seize the important opportunities of new paradigm empowerment and new tracks; with high-level innovation carriers and platforms as important support, gather high-end resources of scientific and technological innovation and industrial innovation, enhance clinical research capabilities, accelerate the cultivation of leading biomedical companies, and promote the "export" of innovative products. Shanghai will use key areas such as Pudong New Area and Minhang District as carriers to promote the characteristic, intensive and large-scale development of industrial parks; at the same time, strengthen policy guarantees, accelerate product listing, promotion and application, and accelerate the construction of a biomedical industry innovation highland with global influence and a world-class biomedical industry cluster.

On the same day, AstraZeneca also launched the "Green Ribbon Liver Cancer Early Screening and Diagnosis Program" in cooperation with Zhongshan Hospital Affiliated to Fudan University , helping to create an innovative model for early screening of liver cancer. It is reported that the program is led by Zhongshan Hospital Affiliated to Fudan University, and the main leaders are Fan Jia, an academician of the Chinese Academy of Sciences and the president of Zhongshan Hospital Affiliated to Fudan University, and Zhou Jian, the vice president of Zhongshan Hospital Affiliated to Fudan University. It will comprehensively promote the screening of high-risk groups for liver cancer, the verification of new technologies for early screening of liver cancer, the promotion of standardized diagnosis and treatment of liver cancer, and carry out popular science education on diseases for the general public.

https://www.vbdata.cn/newsDetail/f82be52ed51611ee8eec00163e034e34